Human B lymphoblastoid cell lines provide an interleukin 1 like signal for mitogen-treated T lymphocytes via direct cell contact

A. Arnold, S. Lipkowitz, Manikkam Suthanthiran, A. Novogrodsky, K. H. Stenzel

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The B lymphoblastoid cell lines (B-LCL) 8392, SB, 1788, and Daudi provide accessory cell activity for mitogen-treated T cells, whereas the T lines MOLT-4, 8402, CEM, and HSB do not provide this function. Direct cell contact is required for the accessory cell activity, and active lymphocyte growth factors could not be detected in the supernatants of the B-LCL. The B-LCL also present alloantigens to responding T cells, and this response is independent of additional accessory cells. The target for the B-LCL is the responding T cell itself, rather than a minor contaminating population of endogenous accessory cells. This conclusion is based on the finding that, under culture conditions in which T cells do not proliferate in response to PHA, accessory cell activity of the B-LCL is maintained. Paraformaldehyde- or glutaraldehyde-treated B-LCL retain their accessory cell activity at levels of these agents that completely eliminate metabolic activity of the B-LCL, as determined by incorporation of leucine, thymidine, and uridine into macromolecules. This treatment eliminates alloantigen presentation by the B-LCL. T cells treated with IO4 - or with monoclonal anti-T3 antibodies fail to respond to highly purified IL 1, and respond minimally to supra-optimal concentrations of IL 2. Nevertheless, these cells respond maximally to the accessory cell activity of the B-LCL. The IO4 --treated cells or cells exposed to anti-T3 also proliferate in response to TPA. Together, our data suggest that the B-LCL provide an IL 1-like signal for mitogen-treated T cells via direct cell contact, in the absence of detectable soluble IL 1.

Original languageEnglish
Pages (from-to)3876-3881
Number of pages6
JournalJournal of Immunology
Volume134
Issue number6
Publication statusPublished - 19 Sep 1985
Externally publishedYes

Fingerprint

Interleukin-1
Mitogens
T-Lymphocytes
Cell Line
Isoantigens
Uridine
Glutaral
Leucine
Thymidine
Interleukin-2
Anti-Idiotypic Antibodies
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Human B lymphoblastoid cell lines provide an interleukin 1 like signal for mitogen-treated T lymphocytes via direct cell contact. / Arnold, A.; Lipkowitz, S.; Suthanthiran, Manikkam; Novogrodsky, A.; Stenzel, K. H.

In: Journal of Immunology, Vol. 134, No. 6, 19.09.1985, p. 3876-3881.

Research output: Contribution to journalArticle

@article{4a2bfb9404414b97b5a25ae429835ee2,
title = "Human B lymphoblastoid cell lines provide an interleukin 1 like signal for mitogen-treated T lymphocytes via direct cell contact",
abstract = "The B lymphoblastoid cell lines (B-LCL) 8392, SB, 1788, and Daudi provide accessory cell activity for mitogen-treated T cells, whereas the T lines MOLT-4, 8402, CEM, and HSB do not provide this function. Direct cell contact is required for the accessory cell activity, and active lymphocyte growth factors could not be detected in the supernatants of the B-LCL. The B-LCL also present alloantigens to responding T cells, and this response is independent of additional accessory cells. The target for the B-LCL is the responding T cell itself, rather than a minor contaminating population of endogenous accessory cells. This conclusion is based on the finding that, under culture conditions in which T cells do not proliferate in response to PHA, accessory cell activity of the B-LCL is maintained. Paraformaldehyde- or glutaraldehyde-treated B-LCL retain their accessory cell activity at levels of these agents that completely eliminate metabolic activity of the B-LCL, as determined by incorporation of leucine, thymidine, and uridine into macromolecules. This treatment eliminates alloantigen presentation by the B-LCL. T cells treated with IO4 - or with monoclonal anti-T3 antibodies fail to respond to highly purified IL 1, and respond minimally to supra-optimal concentrations of IL 2. Nevertheless, these cells respond maximally to the accessory cell activity of the B-LCL. The IO4 --treated cells or cells exposed to anti-T3 also proliferate in response to TPA. Together, our data suggest that the B-LCL provide an IL 1-like signal for mitogen-treated T cells via direct cell contact, in the absence of detectable soluble IL 1.",
author = "A. Arnold and S. Lipkowitz and Manikkam Suthanthiran and A. Novogrodsky and Stenzel, {K. H.}",
year = "1985",
month = "9",
day = "19",
language = "English",
volume = "134",
pages = "3876--3881",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - Human B lymphoblastoid cell lines provide an interleukin 1 like signal for mitogen-treated T lymphocytes via direct cell contact

AU - Arnold, A.

AU - Lipkowitz, S.

AU - Suthanthiran, Manikkam

AU - Novogrodsky, A.

AU - Stenzel, K. H.

PY - 1985/9/19

Y1 - 1985/9/19

N2 - The B lymphoblastoid cell lines (B-LCL) 8392, SB, 1788, and Daudi provide accessory cell activity for mitogen-treated T cells, whereas the T lines MOLT-4, 8402, CEM, and HSB do not provide this function. Direct cell contact is required for the accessory cell activity, and active lymphocyte growth factors could not be detected in the supernatants of the B-LCL. The B-LCL also present alloantigens to responding T cells, and this response is independent of additional accessory cells. The target for the B-LCL is the responding T cell itself, rather than a minor contaminating population of endogenous accessory cells. This conclusion is based on the finding that, under culture conditions in which T cells do not proliferate in response to PHA, accessory cell activity of the B-LCL is maintained. Paraformaldehyde- or glutaraldehyde-treated B-LCL retain their accessory cell activity at levels of these agents that completely eliminate metabolic activity of the B-LCL, as determined by incorporation of leucine, thymidine, and uridine into macromolecules. This treatment eliminates alloantigen presentation by the B-LCL. T cells treated with IO4 - or with monoclonal anti-T3 antibodies fail to respond to highly purified IL 1, and respond minimally to supra-optimal concentrations of IL 2. Nevertheless, these cells respond maximally to the accessory cell activity of the B-LCL. The IO4 --treated cells or cells exposed to anti-T3 also proliferate in response to TPA. Together, our data suggest that the B-LCL provide an IL 1-like signal for mitogen-treated T cells via direct cell contact, in the absence of detectable soluble IL 1.

AB - The B lymphoblastoid cell lines (B-LCL) 8392, SB, 1788, and Daudi provide accessory cell activity for mitogen-treated T cells, whereas the T lines MOLT-4, 8402, CEM, and HSB do not provide this function. Direct cell contact is required for the accessory cell activity, and active lymphocyte growth factors could not be detected in the supernatants of the B-LCL. The B-LCL also present alloantigens to responding T cells, and this response is independent of additional accessory cells. The target for the B-LCL is the responding T cell itself, rather than a minor contaminating population of endogenous accessory cells. This conclusion is based on the finding that, under culture conditions in which T cells do not proliferate in response to PHA, accessory cell activity of the B-LCL is maintained. Paraformaldehyde- or glutaraldehyde-treated B-LCL retain their accessory cell activity at levels of these agents that completely eliminate metabolic activity of the B-LCL, as determined by incorporation of leucine, thymidine, and uridine into macromolecules. This treatment eliminates alloantigen presentation by the B-LCL. T cells treated with IO4 - or with monoclonal anti-T3 antibodies fail to respond to highly purified IL 1, and respond minimally to supra-optimal concentrations of IL 2. Nevertheless, these cells respond maximally to the accessory cell activity of the B-LCL. The IO4 --treated cells or cells exposed to anti-T3 also proliferate in response to TPA. Together, our data suggest that the B-LCL provide an IL 1-like signal for mitogen-treated T cells via direct cell contact, in the absence of detectable soluble IL 1.

UR - http://www.scopus.com/inward/record.url?scp=0021888758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021888758&partnerID=8YFLogxK

M3 - Article

C2 - 2985701

AN - SCOPUS:0021888758

VL - 134

SP - 3876

EP - 3881

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -